SCHEMBL352390

SCHEMBL352390

O=C(OC(=O)[C@H](O)c1ccccc1)C(O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.62
MAPK1 P28482 1/20 0.62
CES2 O00748 2/20 0.56
CES1 P23141 2/20 0.56
HPGD P15428 1/20 0.50
KMT2A Q03164 2/20 0.48
CYP2D6 P10635 3/20 0.47
CYP2C9 P11712 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CHRM2 P08172 2/20 0.46
CHRM1 P11229 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
SRC P12931 2/20 0.46
CHRM4 P08173 1/20 0.46
CHRM5 P08912 1/20 0.46
CHRM3 P20309 1/20 0.46
BLM P54132 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NR1I2 O75469 1/20 0.44
ABCB11 O95342 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951103 1.00 LMNA (0.62) LMNAMAPK1CES2CES1HPGD
SCHEMBL2687707 0.91 LMNA (0.58) LMNAMAPK1CES2CES1HPGD
SCHEMBL8630181 0.90 LMNA (0.52) LMNAMAPK1CES2CES1HPGD
SCHEMBL28860143 0.88 LMNA (0.55) LMNAMAPK1CES2CES1HPGD
SCHEMBL11083519 0.87 LMNA (0.54) LMNAMAPK1CES2CES1HPGD
SCHEMBL378836 0.87 LMNA (0.54) LMNAMAPK1CES2CES1HPGD
SCHEMBL2761810 0.87 LMNA (0.54) LMNAMAPK1CES2CES1HPGD
SCHEMBL1040186 0.87 LMNA (0.54) LMNAMAPK1CES2CES1HPGD
SCHEMBL9764591 0.86 LMNA (0.52) LMNAMAPK1CES2CES1HPGD
Hydrochloric Acid SCHEMBL5367883 0.86 LMNA (0.52) LMNAMAPK1CES2CES1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120093737-A1 LIGHT-ABSORBING COMPOSITIONS AND METHODS OF USE ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC. 2012-04-19 US disclosed
US-20120076842-A1 COSMETIC USE OF TYR-ARG DIPEPTIDE TO COMBAT CUTANEOUS SAGGING SEDERMA (FR) 2012-03-29 US disclosed
EP-2419076-A2 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES Sederma (FR) 2012-02-22 EP disclosed
US-20120028916-A1 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES SEDERMA (FR) 2012-02-02 US disclosed
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES SEDERMA (FR) 2012-01-19 US disclosed
EP-2382231-A2 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES Sederma (FR) 2011-11-02 EP disclosed
EP-2382230-A2 KXK-PEPTIDE COMPOSITIONS FOR COSMETIC AND DERMO-PHARMACEUTIC USES Sederma (FR) 2011-11-02 EP disclosed
US-20110250276-A1 Cosmetic Composition Containing Acetylated Oligoglucuronans SEDERMA, S.A.S. (FR) 2011-10-13 US disclosed
EP-2367852-A1 COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS Sederma (FR) 2011-09-28 EP disclosed
EP-2046283-B1 COMPOSITION COMPRISING SARSASAPOGENIN SEDERMA SA (FR) 2011-03-16 EP disclosed
US-20110045036-A1 Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle SEDERMA (FR) 2011-02-24 US disclosed
US-20110033507-A1 Polypeptides KXK and Their Use SEDERMA (FR) 2011-02-10 US disclosed
US-20110002865-A1 MOISTURIZING COSMETIC COMPOSITION COMPRISING A COMBINATION OF HOMARINE AND ERYTHRITOL SEDERMA, S.A.S. (FR) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES CUTA, PLOD3, MC1R LMNA 1856/4885MAPK1 1934/4885CES2 4406/4885
US-20110033507-A1 Polypeptides KXK and Their Use NPR3, NGLY1, NPR1 LMNA 828/4885MAPK1 3481/4885CES2 4322/4885
US-20120076842-A1 COSMETIC USE OF TYR-ARG DIPEPTIDE TO COMBAT CUTANEOUS SAGGING ARGLU1, CUTA, ARG1 LMNA 3387/4885MAPK1 2953/4885CES2 2466/4885
US-20110045036-A1 Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle TYR, XPA, MC1R LMNA 268/4885MAPK1 2667/4885CES2 2836/4885
US-20110002865-A1 MOISTURIZING COSMETIC COMPOSITION COMPRISING A COMBINATION OF HOMARINE AND ERYTHRITOL AQP1, CUTA, AQP3 LMNA 2297/4885MAPK1 3877/4885CES2 2359/4885
US-20110250276-A1 Cosmetic Composition Containing Acetylated Oligoglucuronans GLA, OGA, CUTA LMNA 620/4885MAPK1 1478/4885CES2 3226/4885
US-20120028916-A1 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES DPM1, MC1R, SLTM LMNA 1393/4885MAPK1 3655/4885CES2 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.